MedTrace Logo

Trial of Immunomodulatory Therapy in High Risk Solitary Bone Plasmacytoma

NCT02544308 · Status: ACTIVE_NOT_RECRUITING · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 36

Last updated 2022-12-23

No results posted yet for this study

Summary

The purpose of the trial is to establish whether adjuvant therapy with lenalidomide + dexamethasone after radiotherapy can improve progression free survival in patients with high risk solitary bone plasmacytoma compared with RT only.

Conditions

  • Plasmacytoma

Interventions

DRUG

Lenalidomide

Experimental Arm

DRUG

Dexamethasone

Experimental Arm

OTHER

No further treatment

Comparator Arm

Sponsors & Collaborators

  • Cancer Research UK

    collaborator OTHER

  • Celgene

    collaborator INDUSTRY

  • University College, London

    lead OTHER

Principal Investigators

  • Roger Owen · St James's University Hospital

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2017-03-10
Primary Completion
2026-04-30
Completion
2026-12-31
FDA Drug
Yes

Countries

  • United Kingdom

Study Locations

More Related Trials

Entities

Drugs
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02544308 on ClinicalTrials.gov